ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,923.82
-0.23%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Genesis Healthcare Inc (GEN)

  7. Genesis Healthcare Inc (GEN) Noticias

GEN

Genesis Healthcare (GEN)

Genesis Healthcare Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NYSE:GEN
FechaHoraFuenteTítuloSímboloCompañía
24/01/202305:27GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022NYSE:GENGenesis Healthcare Inc
10/11/202219:49TipRanksRBC Capital Keeps Their Hold Rating on Gen Digital (GEN)NYSE:GENGenesis Healthcare Inc
09/11/202210:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2022NYSE:GENGenesis Healthcare Inc
03/11/202211:45GlobeNewswire Inc.Genmab Improves Its 2022 Financial GuidanceNYSE:GENGenesis Healthcare Inc
18/10/202205:35GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022NYSE:GENGenesis Healthcare Inc
05/10/202214:56GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
10/08/202210:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2022NYSE:GENGenesis Healthcare Inc
19/07/202205:33GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022NYSE:GENGenesis Healthcare Inc
18/07/202209:01GlobeNewswire Inc.Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NYSE:GENGenesis Healthcare Inc
30/06/202213:24GlobeNewswire Inc.Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
09/06/202216:17GlobeNewswire Inc.Genmab Commences New Arbitration Under License Agreement With JanssenNYSE:GENGenesis Healthcare Inc
11/05/202210:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2022NYSE:GENGenesis Healthcare Inc
19/04/202205:29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022NYSE:GENGenesis Healthcare Inc
13/04/202216:25GlobeNewswire Inc.Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
07/04/202218:44GlobeNewswire Inc.Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License AgreementNYSE:GENGenesis Healthcare Inc
24/02/202205:01GlobeNewswire Inc.Notice to Convene the Annual General Meeting of Genmab A/SNYSE:GENGenesis Healthcare Inc
16/02/202210:00GlobeNewswire Inc.Genmab Publishes 2021 Annual ReportNYSE:GENGenesis Healthcare Inc
25/01/202205:30GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021NYSE:GENGenesis Healthcare Inc
04/01/202208:00GlobeNewswire Inc.Genmab and Synaffix Enter into License Agreement for ADC TechnologyNYSE:GENGenesis Healthcare Inc
10/11/202110:00GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2021NYSE:GENGenesis Healthcare Inc
04/11/202115:24GlobeNewswire Inc.Genmab Improves its 2021 Financial GuidanceNYSE:GENGenesis Healthcare Inc
19/10/202105:29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021NYSE:GENGenesis Healthcare Inc
21/09/202113:22GlobeNewswire Inc.Capital Increase in Genmab as a Result of Employee Warrant ExerciseNYSE:GENGenesis Healthcare Inc
20/09/202116:00GlobeNewswire Inc.Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical CancerNYSE:GENGenesis Healthcare Inc
11/08/202110:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2021NYSE:GENGenesis Healthcare Inc
21/07/202105:31GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021NYSE:GENGenesis Healthcare Inc
22/06/202109:12GlobeNewswire Inc.Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formul...NYSE:GENGenesis Healthcare Inc
28/05/202115:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:GENGenesis Healthcare Inc
21/05/202108:08GlobeNewswire Inc.Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Form...NYSE:GENGenesis Healthcare Inc
05/05/202110:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2021NYSE:GENGenesis Healthcare Inc
 Showing the most relevant articles for your search:NYSE:GEN

Su Consulta Reciente

NASDAQ
VLYWW
Valley National Bancorp
BIT
S28172
Societe Generale Effekten
LSE
56IL
Ubs 8.75% 2025
NYSE
JZZ.L
BIT
S29323
Societe Generale Effekten
BIT
STIT5S
SG Issuer Societe Generale
BIT
P1OYI5
BNP Paribas Issuance
COIN
FLETAKRW
Fleta Token
GDAX
ADAETH
Cardano
NASDAQ
FZCWMX
Vest Large Cap Deep Buff...
TG
PEP
PepsiCo
LSE
12HO
Westpac 2031
LSE
0MXU
Osivo As
NYSE
CKH
Seacor
COIN
SFILETH
FileCoin standard Full hashrate
BIT
F16871
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados